HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
The main purpose of the study is to describe changes in plasma HPV DNA levels in patients
 with locally advanced cervical cancer during radical radiochemotherapy (CRT) and to correlate
 changes with response to treatment. Monitoring of the response to treatment will also be
 assessed in FDG PET CT imaging.
Ninety-five per cent of cervical cancer cases are caused by persistent infections with
 carcinogenic HPVs. Locally advanced stage IB2 to IVA cervical cancers are treated with
 definitive chemoradiation therapy (CRT). Despite known clinical prognostic factors of poor
 treatment outcome such as advanced stage and positive nodal status, we still don't know
 predictors of relapse.

 HPV status will be assessed in the neoplastic tissue and DNA from the blood serum of patients
 with cervical cancer will be isolated and analyzed by real-time PCR. Plasma HPV DNA would
 identify patients with residual disease after CRT due to persistent detectable HPV. This
 would earlier detect high risk patients who would benefit from adjuvant therapy.

 While metabolic response in post - therapy FDG PET CT is predictive of survival, there is
 usually 3 months waiting period time needed to perform this imaging. This pilot study will
 provide preliminary estimates of the correlation between plasma HPV DNA level, PET finding
 and clinical outcome in polish cervical cancer patients.
Inclusion Criteria:

 Age Limits: more than 18Y Histologically confirmed squamous cell carcinoma, FIGO stage
 IB-IVA planned for radical radiochemotherapy Eastern Cooperative Oncology Group (ECOG)
 performance status 0,1,2

 Exclusion Criteria:

 Patients who have received any anticancer treatment for their cervical cancer. Eastern
 Cooperative Oncology Group (ECOG) performance status > 2 Other cervical cancer tumor
 histologies (e.g. small cell, serous) Contraindications to 18FDG PET-CT Contraindication to
 radiochemotherapy Known pregnancy or lactating